CSIMarket
 


Myriad Genetics Inc   (MYGN)
Other Ticker:  
 
 

MYGN's EPS Net Growth by Quarter and Year

Myriad Genetics Inc 's EPS Net results by quarter and year




MYGN EPS Net (in $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December -0.36 -0.52 -0.10 -0.20
III Quarter September -0.75 -0.43 0.30 -0.74
II Quarter June -1.42 -0.18 -0.06 -1.55
I Quarter March -0.67 -0.26 -0.52 -0.11
FY   -3.20 -1.39 -0.38 -2.60



MYGN EPS Net fourth quarter 2023 Y/Y Growth Comment
Myriad Genetics Inc in the fourth quarter 2023 recorded EPS net loss of $ -0.36 .

According to the results reported in the fourth quarter 2023, Myriad Genetics Inc achieved the best EPS Net growth in In Vitro & In Vivo Diagnostic Substances industry. While Myriad Genetics Inc ' s EPS Net no change of % ranks overall at the positon no. in the fourth quarter 2023.




MYGN EPS Net ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Myriad Genetics Inc 's fourth quarter 2023 EPS Net $ -0.36 MYGN's Income Statement
Myriad Genetics Inc 's fourth quarter 2022 EPS Net $ -0.52 Quarterly MYGN's Income Statement
New: More MYGN's historic EPS Net Growth >>


MYGN EPS Net (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




EPS Net fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

EPS Net Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
EPS Net fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
EPS Net Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

EPS Net by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Myriad Genetics Inc 's Q/Q EPS Net Growth


EPS Net Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


MYGN's IV. Quarter Q/Q EPS Net Comment
Even if Myriad Genetics Inc in the IV. Quarter 2023 showed EPS net loss of $ -0.36 , management said, that this show slight up side compare to the -0.75 in the third quarter.

Within In Vitro & In Vivo Diagnostic Substances industry Myriad Genetics Inc achieved highest sequential EPS Net growth. While Myriad Genetics Inc 's EPS Net growth quarter on quarter, overall rank is .


EPS Net Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
EPS Net Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
EPS Net Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


MYGN's IV. Quarter Q/Q EPS Net Comment
Despite the fact, that Myriad Genetics Inc in the IV. Quarter 2023 showed EPS net loss of $ -0.36 , management point out, that this point to slight up side relative to the -0.75 in the third quarter.

Within In Vitro & In Vivo Diagnostic Substances industry Myriad Genetics Inc achieved highest sequential EPS Net growth. While Myriad Genetics Inc 's EPS Net growth quarter on quarter, overall rank is .


Myriad Genetics Inc 's 12 Months EPS Net Growth Year on Year


EPS Net TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative EPS Net 12 Months Ending $ -3.20 $ -3.36 $ -3.04 $ -1.80 $ -1.39
Y / Y EPS Net Growth (TTM) - - - - -
Year on Year EPS Net Growth Overall Ranking # # # # #
Seqeuential EPS Net Change (TTM) - - - - -
Seq. EPS Net Growth (TTM) Overall Ranking # # # # #




Cumulative EPS Net growth Comment
Myriad Genetics Inc ' has realized cumulative trailing twelve months EPS net loss of $ -3 in the Dec 31 2023 period.

Myriad Genetics Inc achieved highest trailing twelve month year on year EPS Net growth. While overall EPS Net growth ranking, remained unchanged compare to the previous quarter at no. .

EPS Net TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

EPS Net TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

EPS Net TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


EPS Net TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative EPS Net growth Comment
Myriad Genetics Inc ' has realized cumulative trailing twelve months EPS net loss of $ -3 in the Dec 31 2023 period.

Myriad Genetics Inc achieved highest trailing twelve month year on year EPS Net growth. While overall EPS Net growth ranking, remained unchanged compare to the previous quarter at no. .

EPS Net TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


EPS Net TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

EPS Net TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


EPS Net TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other EPS Net Growth
In Vitro & In Vivo Diagnostic Substances Industry EPS Net Growth Trends and Statistics
Healthcare Sector EPS Net Growth Statistics
EPS Net Growth Trends for overall market
MYGN's EPS Net Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking EPS Net Growth
Lowest Ranking EPS Net Growth
EPS Net Growth for MYGN's Competitors
EPS Net Growth for Myriad Genetics Inc 's Suppliers
EPS Net Growth for MYGN's Customers

You may also want to know
MYGN's Annual Growth Rates MYGN's Profitability Ratios MYGN's Asset Turnover Ratio MYGN's Dividend Growth
MYGN's Roe MYGN's Valuation Ratios MYGN's Financial Strength Ratios MYGN's Dividend Payout Ratio
MYGN's Roa MYGN's Inventory Turnover Ratio MYGN's Growth Rates MYGN's Dividend Comparisons



Companies with similar EPS Net no change for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %EPS Net for the quarter ending Dec 31 2023
Charles River Laboratories International inc -1.31%$ -1.311 
Encompass Health Corporation-3.73%$ -3.731 
Regeneron Pharmaceuticals Inc -4.07%$ -4.066 
Haemonetics Corporation-4.69%$ -4.688 
Edwards Lifesciences Corporation-5.96%$ -5.957 
Resmed Inc -7.19%$ -7.190 
Bristol myers Squibb Company-8.78%$ -8.778 
Avenue Therapeutics Inc -11.55%$ -11.547 
Gilead Sciences Inc -11.97%$ -11.969 
Utah Medical Products Inc-14.08%$ -14.084 
Masimo Corp-18.55%$ -18.550 
Merit Medical Systems Inc-18.93%$ -18.927 
Qiagen N v -19.57%$ -19.565 
Avantor Inc -22.62%$ -22.616 
Fresenius Medical Care Ag-26.09%$ -26.087 
Mettler toledo International Inc -28.51%$ -28.506 
Star Equity Holdings Inc -29.22%$ -29.218 
Harmony Biosciences Holdings inc -38.72%$ -38.717 
Amedisys Inc -39.32%$ -39.315 
Avanos Medical Inc -39.47%$ -39.469 
Pro dex Inc -41.67%$ -41.667 
Embecta Corp -42.62%$ -42.623 
Becton Dickinson And Company-43.53%$ -43.529 
Bio techne Corp-45.16%$ -45.161 
Amgen Inc -52.98%$ -52.977 
Biogen Inc -55.59%$ -55.590 
Taro Pharmaceutical Industries Ltd-56.13%$ -56.129 
Bio rad Laboratories Inc -56.74%$ -56.736 
Integra Lifesciences Holdings Corp-60.46%$ -60.461 
Henry Schein Inc-60.47%$ -60.467 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com